Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd. (China) is currently conducting a Phase I trial, which is a single-center, single-arm, open-label study aimed at evaluating the safety and efficacy of CAR-T cell therapy targeting EphA2 expressed on various solid tumors, including pancreatic cancer (NCT05003895). The gene discussed is EPHA2; the disease is familial pancreatic carcinoma.